Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Electrolyte disorders related to EGFR-targeting drugs.

Izzedine H, Bahleda R, Khayat D, Massard C, Magné N, Spano JP, Soria JC.

Crit Rev Oncol Hematol. 2010 Mar;73(3):213-9. doi: 10.1016/j.critrevonc.2009.03.012. Epub 2009 Apr 28. Review.

PMID:
19403315
2.

Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.

Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G.

Am J Kidney Dis. 2007 Aug;50(2):203-18. Review.

PMID:
17660022
3.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

4.

Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents.

Costa A, Tejpar S, Prenen H, Van Cutsem E.

Target Oncol. 2011 Dec;6(4):227-33. doi: 10.1007/s11523-011-0200-y. Epub 2011 Nov 24. Review.

PMID:
22113391
6.

Molecular mechanisms and targeting of colorectal cancer.

Vanhoefer U.

Semin Oncol. 2005 Dec;32(6 Suppl 8):7-10. Review.

PMID:
16360005
7.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

8.

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS.

Cancer Res. 2001 Jul 1;61(13):5090-101.

9.
10.

[Nephrotoxicity--proteinuria and hypertension--].

Ando M.

Gan To Kagaku Ryoho. 2008 Oct;35(10):1649-53. Japanese.

PMID:
18931564
12.

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G.

Clin Cancer Res. 2008 Aug 15;14(16):5069-80. doi: 10.1158/1078-0432.CCR-07-4905. Epub 2008 Aug 11.

13.

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.

Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS.

Mol Cancer Ther. 2007 Feb;6(2):471-83.

15.

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

Press MF, Lenz HJ.

Drugs. 2007;67(14):2045-75. Review.

PMID:
17883287
16.
18.

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.

Bellmunt J, Hussain M, Dinney CP.

Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S85-104. Review.

PMID:
12850530
19.
20.

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G.

Clin Cancer Res. 2000 Sep;6(9):3739-47.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk